StockMacro
Menu

Iambic Therapeutics

$13.11 -31% in 6 monthsMarket cap $621.4M

IAM on XNAS, Health Care, Iambic Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Insiders bought $11.5M of stock and sold none, while the company filed two share registrations.

  • WatchPast S-1 filers trailed sector by median 23.8 points in six months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Iambic Therapeutics Inc is a technology and clinical-stage life sciences company developing novel medicines using its proprietary molecular superintelligence platform.

Industry
Biological products, (no diagnostic substances) (Health Care)
Website
iambic.ai
Listed
Nasdaq, US
Last results
16 Nov 2026
Next results
no estimate
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. – –
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $252.0M –
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $76.9M –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$175.2M (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. – 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Iambic TherapeuticsIAM (this company) $621.4M––––
Cullinan TherapeuticsCGEM $577.1Mloss–––
4D Molecular TherapeuticsFDMT $576.8Mloss6.0+79952%-209%
Entera BioENTX $575.5Mloss–––
Attovia TherapeuticsATTO $690.3M––––
Solid BiosciencesSLDB $697.6Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$11.5M

bought $11.5M, sold $0

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

–

No data for this company

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

–

No 13F holdings or share count.

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

2.2%

1.1M shares sold short (30 Oct 2026) of 48.9M outstanding (16 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.2

1.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

–

1.1M shares sold short (30 Oct 2026); no report before it to compare with

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

46%

46% of off-exchange volume on 20 Nov 2026 was short sales

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

28

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

18

18 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

18×

18 articles in the last 7 days; its usual week has 1.

Price $13.11 on 20 Nov 2026, -31% over 12 months (12-month range $10.17 to $23.81)

  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $11.5M in the last 12 months (the 12 months before: $0).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $11.4M in the latest quarter, +142% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: capital spending per quarter, institutional holders (13f filers), federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
8 Oct 20268-K and other filingsRegistered new securities for sale (S-1)
21 Sep 20268-K and other filingsRegistered new securities for sale (S-1)
9 Sep 20268-K and other filingsPrivate placement of securities (Form D)
8 Apr 20268-K and other filingsPrivate placement of securities (Form D)
21 Nov 20258-K and other filingsPrivate placement of securities (Form D)
25 Apr 20248-K and other filingsPrivate placement of securities (Form D)
12 Oct 20238-K and other filingsPrivate placement of securities (Form D)
Insider net buying (open market)
Month from 1 Oct 2026: $11.5M published
H-1B/E-3 applications certified
Quarter from 1 Apr 2026: 1 published
Revenue per quarter
Quarter ended 30 Sep 2025: $4.7M; public on 20 Nov 2026
Quarter ended 30 Sep 2026: $11.4M, +142% on a year earlier; public on 20 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is total liabilities at period end at $207.2M (30 Sep 2026), 5.1× its normal quarter.
  • Insider net buying (open market): Insiders bought a net $11.5M in the last 12 months (the 12 months before: $0).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
  • Revenue per quarter: Revenue $11.4M in the latest quarter, +142% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 1 insider trades

Last 90 days: no sales; 1 purchase, $11.5M. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
19 Oct 2026Evan Lockwood RachlinDirectorBuy718,750$16.00$11.5MForm 4

Company events

All 7 company events

In 12 months: 2 private placements, 2 share registrations. Results releases and routine reports are left out.

FiledWhat happenedSource
8 Oct 2026Registered new securities for sale (S-1)S-1/A
21 Sep 2026Registered new securities for sale (S-1)S-1
9 Sep 2026Private placement of securities (Form D)$66.0M sold of $66.5M offeredD
8 Apr 2026Private placement of securities (Form D)$27.8M sold of $50.0M offeredD
21 Nov 2025Private placement of securities (Form D)$99.3M sold of $125.0M offeredD
25 Apr 2024Private placement of securities (Form D)$26.9M sold of $38.0M offeredD
12 Oct 2023Private placement of securities (Form D)$103.2M sold of $110.0M offeredD

28 open postings; careers site tracked since 20 Nov 2026. Most in Research & science 36%, Legal, policy & compliance 18%, ML / AI 18%, Finance & accounting 7%.

PostedJobLocation
18 Nov 2026Sr. Software Engineer, Lab AutomationSoftware engineeringSan Diego HQ
16 Nov 2026Executive Director of SafetyLegal, policy & complianceSan Diego HQ; Remote - US
16 Nov 2026Associate Scientist II or Senior Associate Scientist, ImmunologyResearch & scienceSan Diego HQ
6 Nov 2026Research Scientist II/Senior Research Scientist, Medicinal ChemistryResearch & scienceSan Diego HQ
6 Nov 2026Sr Manager, Enterprise Business SystemsCorporate ITSan Diego HQ
4 Nov 2026Associate Director/Director, FP&AFinance & accountingSan Diego HQ
4 Nov 2026Sr Manager, FP&A - Discovery R&DFinance & accountingSan Diego HQ
2 Nov 2026Director, IP CounselLegal, policy & complianceSan Diego HQ

The 5 newest of 147 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 19 Oct 2026Insiders record

    Rachlin Evan Lockwood (director) bought 718,750 shares of IAM ($11.5M)

  2. 8 Oct 2026Filings record

    Registered new securities for sale (S-1)

  3. 21 Sep 2026Filings record

    Registered new securities for sale (S-1)

  4. 9 Sep 2026Filings record

    Private placement of securities (Form D)

  5. 8 Apr 2026Filings record

    Private placement of securities (Form D)

  6. 21 Nov 2025Filings record

    Private placement of securities (Form D)

  7. 25 Apr 2024Filings record

    Private placement of securities (Form D)

  8. 12 Oct 2023Filings record

    Private placement of securities (Form D)

Not listed: 2 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001997038
Ticker
IAM
Domain
iambic.ai
Employer name
Iambic Therapeutics, Inc. (1 unverified)
Fein
84-3364168 (1 unverified)
Hq location
CA|SAN DIEGO|92121 (1 unverified)
Name
Iambic Therapeutics, Inc.
  • DOL H-1B labor condition applications and PERM certifications5 data points2 Mar 2026 to 2 Mar 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)9 records12 Oct 2023 to 19 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)28 data points31 Dec 2024 to 16 Nov 2026
  • SEC Form 4 insider transactions1 record, 4 data points19 Oct 2026 to 19 Oct 2026
  • FINRA short interest (twice monthly)55 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)130 data points7 Aug 2018 to 20 Nov 2026